The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Advancements in prolonging remission post-transplant in myeloid malignancies
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the significant challenge of prolonging remission following allogeneic stem cell transplantation (alloSCT) in myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Guru Murthy highlights the advancements in identifying patients at high risk of relapse and comments on the potential for adjusting transplant strategies and post-transplant care based on these insights to improve patient outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
